131I联合甲磺酸阿帕替尼对难治性甲状腺癌细胞的抑制作用及机制研究

doi:10.11904/j.issn.1002-3070.2020.02.010

实用肿瘤学杂志 ›› 2020, Vol. 34 ›› Issue (2): 139-143.doi: 10.11904/j.issn.1002-3070.2020.02.010

¹³¹I联合甲磺酸阿帕替尼对难治性甲状腺癌细胞的抑制作用及机制研究

吴丹, 王路, 王兴华, 崔亚利

哈尔滨医科大学附属肿瘤医院核医学科(哈尔滨 150081)

收稿日期:2020-01-07 发布日期:2020-04-27
通讯作者: 崔亚利,E-mail:yalicui68@126.com
作者简介:吴丹,女,(1994-),硕士研究生,从事甲状腺癌¹³¹I治疗的研究。
基金资助:
哈尔滨医科大学附属肿瘤医院海燕基金(编号:JJZD2018-02)

Inhibitory effect and mechanism of ¹³¹I combined with apatinib on refractory thyroid cancer cells

WU Dan, WANG Lu, WANG Xinghua, CUI Yali

1.Department of Nuclear Medicine,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2020-01-07 Published:2020-04-27

摘要/Abstract

摘要： 目的探讨¹³¹I联合血管生成抑制剂甲磺酸阿帕替尼对难治性甲状腺癌细胞的抑制作用及其机制。方法将难治性甲状腺癌细胞分为对照组、¹³¹I组、阿帕替尼组及¹³¹I联合阿帕替尼治疗组(联合组),使用噻唑蓝(MTT)法检测各组肿瘤细胞治疗24 h、48 h后的增殖率;采用免疫荧光方法及蛋白印迹法检测各组细胞凋亡蛋白Caspase-3和血管生成蛋白VEGF的表达。结果联合组处理后细胞的增殖率明显低于其它各组,差异具有统计学意义(P＜0.05)。联合组Caspase-3蛋白的表达含量明显高于其它各组(P＜0.01),联合组VEGF蛋白的相对表达量显著低于其它各组(P＜0.01)。结论 ¹³¹I联合甲磺酸阿帕替尼作用于难治性甲状腺癌细胞时具有协同增效作用,¹³¹I联合甲磺酸阿帕替尼通过上调促凋亡蛋白Caspase-3,下调VEGF的表达水平以达到增强¹³¹I抑制难治性甲状腺癌的增殖作用,从而为难治性甲状腺癌的临床治疗提供较好的策略。

关键词: ¹³¹I, 甲磺酸阿帕替尼, 难治性甲状腺癌细胞, Caspase-3, 血管内皮生长因子

Abstract: Objective The Objective of this study was to investigate the inhibitory effect of ¹³¹I combined with angiogenesis inhibitor apatinib on refractory thyroid cancer cells and its mechanism.Methods The refractory thyroid cancer cells were divided into the control group,¹³¹I group,apatinib group,and ¹³¹I combined with apatinib group(combined group).After treatment for 24 and 48 h,the proliferation of thyroid cancer cells was determined by thiazolyl blue(MTT)assay.The expression of Caspase-3 and VEGF proteins was determined by immunofluorescence and Western blot.Results The proliferative rate of refractory thyroid cancer cells in the combined group was significantly lower than that in the other groups,and the difference was statistically significant(P＜0.01).The expression of Caspase-3 protein in the combined group was significantly higher than that in the other groups(P＜0.01),and the expression of VEGF protein in the combined group was significantly lower than that in the other groups(P＜0.01).Conclusion ¹³¹I combined with apatinib has synergistic effect on refractory thyroid cancer cells.This combination can up-regulate the pro-apoptotic protein Caspase-3 and down-regulate the expression of VEGF protein to inhibit the proliferation of refractory thyroid cancer cells.Thus,this will provide a better strategy for clinical treatment of refractory thyroid cancer.

Key words: ¹³¹I, Apatinib, Radioactive iodine-refractory differentiated thyroid cancer cells, Caspase-3, VEGF

中图分类号:

R736.1

吴丹, 王路, 王兴华, 崔亚利. ¹³¹I联合甲磺酸阿帕替尼对难治性甲状腺癌细胞的抑制作用及机制研究[J]. 实用肿瘤学杂志, 2020, 34(2): 139-143.

WU Dan, WANG Lu, WANG Xinghua, CUI Yali. Inhibitory effect and mechanism of ¹³¹I combined with apatinib on refractory thyroid cancer cells[J]. Journal of Practical Oncology, 2020, 34(2): 139-143.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.02.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I2/139

参考文献

1 Haugen BR,Alexander EK,Bible KC,et al.2015 American thyroid association management guidelines or adult patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133.
2 Zehnder AM,Swift LA,Sundaram A,et al.Clinical features,treatment,and outcomes of cutaneous and oral squamous cell carcinoma in avian species[J].J Am Vet Med Assoc,2018,252(3):309-315.
3 Pitoia F,Jerkovich F.Selective use of sorafenib in the treatment ofthyroid cancer[J].Drug Des Dev Ther,2016,10:1119-1131.
4 Schlumberger M,Tahara M,Wirth LJ,et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J].N Engl J Med,2015,12,372(7):621-630.
5 Ghosh RD,Ghuwalewala S,Das P,et al.MicroRNA profiling of cisplatin-resistant oralsquamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features[J].Sci Rep,2016,6:23932.
6 Dewan MZ,Galloway AE,Kawashima N,et al.Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal efect when combined with anti-CTLA-4 antibody[J].Clin.Cancer Res,2009,15(17):5379-5388.
7 Zhao D,Jin X,Li F,et al.Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2[J].J Nucl Med,2012,53(12):1872-1877.
8 Li Q,Zhang Y,Elnaggar AK,et al.Therapeutic efficacy of p53 restoration in mdm2-overexpressing tumors[J].Molecular Cancer Research Mcr,2014,12(6):901-911.
9 Jing FJ,Liang J,Liang ZY,et al.BRAFV600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma[J].Chin Med J,2013,126(16):3013-3018.
10 Durante C,Hanndy N,Baudin E,et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy[J].J Clin Endocrinol Metab,2006,91(8):2892-2899.
11 Demaria S,Ng B,Devitt M,et al.Ionizing radiation inhibition of distant untreated tumors(abscopal efect)is immune mediated[J].Int.J.Radiat.Oncol,2004,58(3):862-870.
12 赵倩妤,孙轶华.拉曼光谱在癌症组织学诊断中的研究进展[J].实用肿瘤学杂志,2018,32(1):92-96.
13 Li J,Qin S,Xu J,et al.Randomized,double-blind,placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol,2016,34(13):1448-1454.
14 Schlumberger M,Brose M,Eliset R,et al.Definition and management of radioactive iodine-refractory differentiated thyroid cancer[J].Lancet Diabetes Endocrinol,2014,2(5):356-358.
15 Wiegering A,Korb D,Thalheimer A,et al.E7080(Lenvatinib),a multi-targeted tyrosine kinase inhibitor,demonstrates antitumor activities against colorectal cancer xenografts[J].Neoplasia,2014,16(11):972-981.
16 Tuttle RM.Risk-adapted management of thyroid cancer[J].Endocr Pract,2008,14(6):764-774.

[1]	安巍巍, 唐雅莉, 赵莲花, 杨悦, 王新玲. 红松松塔提取物多聚苯丙素-多糖复合物诱导人乳腺癌MCF-7细胞凋亡[J]. 实用肿瘤学杂志, 2019, 33(4): 289-293.
[2]	代欣综述, 张大昕审校. 非小细胞肺癌抗血管生成治疗研究现状[J]. 实用肿瘤学杂志, 2017, 31(5): 472-476.
[3]	张锐，王智煜，王帅，赵晖. 重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 527-522.
[4]	程卫,赵华. 重组人促甲状腺激素辅助¹³¹I在儿童和青少年分化型甲状腺癌的临床研究[J]. 实用肿瘤学杂志, 2016, 30(4): 309-313.
[5]	王静, 封安强, 张南征. 天然14肽生长抑素联合5-Fu对胃癌移植瘤的抑制作用[J]. 实用肿瘤学杂志, 2016, 30(3): 214-219.
[6]	陈龙综述, 钱诚审校. 血管内皮生长因子基因多态性与乳腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 284-286.
[7]	王迪¹, 何月涵², 王兴华¹, 于红波¹, 王玉君¹, 崔亚利¹. 青少年分化型甲状腺癌¹³¹I治疗的临床观察[J]. 实用肿瘤学杂志, 2015, 29(3): 193-196.
[8]	李晓莉,高伊娜,李建慧,王艳颖,马玉彦. TIP30和VEGF-C在小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2015, 29(2): 116-121.
[9]	邱子丹, 李建成. 食管癌靶向治疗研究进展[J]. 实用肿瘤学杂志, 2015, 29(1): 57-60.
[10]	王云萱, 张清媛, 赵红, 解丽, 田文静, 马新星. CXCR7和VEGF在乳腺癌中的表达及其临床意义[J]. 实用肿瘤学杂志, 2013, 27(4): 340-343.
[11]	林梅,夏百荣,高舒. MTDH和VEGF-C在上皮性卵巢癌组织中的表达及其临床病理特征[J]. 实用肿瘤学杂志, 2013, 27(3): 229-233.
[12]	刘婷婷, 韩波. VEGF与非小细胞肺癌放射治疗研究进展[J]. 实用肿瘤学杂志, 2012, 26(6): 564-568.
[13]	耿淑美, 赵素彦, 张晓伟, 马旭东, 董静, 贾喜花. 检测腹水中血管内皮生长因子对晚期卵巢癌维持治疗的临床意义[J]. 实用肿瘤学杂志, 2012, 26(5): 443-448.
[14]	杨宪广, 孙冀. VEGF研究进展及其在喉癌中的相关研究[J]. 实用肿瘤学杂志, 2011, 25(6): 575-578.
[15]	隋新, 孙志忠, 天亮, 龚显峰. 2,3′,4,4′-四甲氧基联苯对人宫颈癌HeLa细胞增殖的影响[J]. 实用肿瘤学杂志, 2011, 25(4): 325-328.

¹³¹I联合甲磺酸阿帕替尼对难治性甲状腺癌细胞的抑制作用及机制研究

Inhibitory effect and mechanism of ¹³¹I combined with apatinib on refractory thyroid cancer cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价